AlphaValue Corporate Services
This research has been commissioned and paid for by the company and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II


Bloomberg   ALCJ FP
Supergenerics  /  France  Web Site   |   Investors Relation
Still some way to go...
Upside 240%
Price (€) 3.36
Market Cap (€M) 122
Perf. 1W: -1.03%
Perf. 1M: 1.97%
Perf. 3M: -28.2%
Perf Ytd: 1.97%
10 day relative perf. to stoxx600: 1.13%
20 day relative perf. to stoxx600: 0.68%
EPS change18/08/2021

Change in EPS2021 : € 0.18 vs 0.18-0.32%
2022 : € 0.91 vs 0.91-0.32%

We have only integrated the detailed numbers for FY20, which translate into a slightly lower EPS. However, the change is not meaningful given the still very low level of results of the company before its products reach the market.


17 Dec 21 Financing issue
New financing

24 Sep 21 Earnings/sales releases
H1 21: unsurprising (as usual)

31 Mar 21 Earnings/sales releases
FY20 unsuprising; waiting for more

15 Dec 20 Financing issue
A double bond issue

21 Sep 20 Earnings/sales releases
Update on the group's business